SCHEMBL6288530

SCHEMBL6288530

O=C(O)c1ncccc1-c1ccsc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
CYP3A4 P08684 2/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
BLM P54132 1/20 0.47
AGER Q15109 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP2A6 P11509 3/20 0.45
CYP2B6 P20813 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
CHEK2 O96017 2/20 0.44
CYP1A2 P05177 1/20 0.42
GPR35 Q9HC97 1/20 0.41
TOP1 P11387 1/20 0.40
NPC1 O15118 1/20 0.40
CYP2E1 P05181 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28279600 0.80 KDM4E (0.53) KDM4ECYP3A4MAPTALDH1A1ALOX15
SCHEMBL287699 0.79 KDM4E (0.57) KDM4ECYP3A4MAPTALDH1A1ALOX15
SCHEMBL5174868 0.74 KDM4E (0.62) KDM4ECYP3A4MAPTALDH1A1ALOX15
SCHEMBL2512862 0.74 KDM4A (0.49) KDM4ECYP3A4MAPTALDH1A1ALOX15
SCHEMBL28222564 0.74 CYP2A6 (0.52) CYP3A4BLMCYP2A6CYP2B6CYP2C9
SCHEMBL2323790 0.73 KDM4E (0.50) KDM4ECYP3A4MAPTALDH1A1ALOX15
SCHEMBL5258713 0.73 KDM4E (0.50) KDM4ECYP3A4MAPTALDH1A1ALOX15
SCHEMBL3390642 0.73 KDM4E (0.59) KDM4ECYP3A4MAPTALDH1A1ALOX15
SCHEMBL2563987 0.73 KDM4E (0.42) KDM4ECYP3A4MAPTALDH1A1ALOX15
SCHEMBL15730156 0.73 CYP2A6 (0.50) CYP3A4CYP2A6CYP2B6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903097-B2 Heterocycle carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY (US) 2005-06-07 US disclosed
US-20040142928-A1 Heterocycle carboxamides as antiviral agents BUNDY GORDON L (US) 2004-07-22 US disclosed
US-20030207880-A1 Heterocycle carboxamides as antiviral agents BUNDY GORDON L (US) 2003-11-06 US disclosed
US-6559145-B2 Herpes virus PHARMACIA & UPJOHN COMPANY 2003-05-06 US disclosed
EP-1301493-A2 HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-04-16 EP disclosed
US-20020025960-A1 Heterocycle carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-02-28 US disclosed
WO-2002004444-A2 HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO disclosed
US-3963733-A 3-(P-methoxybenzylthio)2-non-oxocarbonylic pyridines SMITHKLINE CORPORATION (US) 1976-06-15 US disclosed
US-3963733-A 3-(P-methoxybenzylthio)2-non-oxocarbonylic pyridines SMITHKLINE CORPORATION (US) 1976-06-15 US disclosed
US-3873552-A Process and intermediates for preparing 3-thiolpicolnic acid SMITHKLINE BECKMAN CORPORATION 1975-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142928-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 KDM4E 201/4885CYP3A4 851/4885MAPT 4388/4885
US-20020025960-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 KDM4E 201/4885CYP3A4 851/4885MAPT 4388/4885
US-20030207880-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 KDM4E 201/4885CYP3A4 851/4885MAPT 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.